Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen

John Carroll Genentech has moved to the head of a small group of players in the anti-inflammatory arena, bagging rights to an antibody that scrambles the connection between IL-33 and ...

FDA bans products from China plant used by Big Pharma players

Emily Wasserman A Chinese ingredient maker who has produced ingredients for some of the big guns in pharma including Novartis, Sanofi and Pfizer is getting its products banned by the ...

Want the skinny from the J.P. Morgan Healthcare Conference? We’ve got you covered

Carly Helfand SAN FRANCISCO–Sometimes, it can tough to be filter out what a company means from the little it says at the J.P. Morgan Healthcare Conference. So please, allow us ...

Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

Damian Garde In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna ...

Vertex’s 2016 outlook falls short amid mixed results from high-profile CF meds

Carly Helfand SAN FRANCISCO–Cystic fibrosis specialist Vertex announced 2015 Kalydeco sales that topped analyst expectations, in advance of a presentation at the ...

Mylan demands payback from Strides on plants targeted by FDA

Tracy Staton Mylan recently got hammered by the FDA in a warning letter for three plants that it acquired as part of its $ 1.75 billion acquisition of the sterile injectables business ...

Dr. Reddy’s blasted in warning letter for hiding existence of testing lab from FDA

Eric Palmer An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to ...

‘Pfizergan’ talks prompt new anti-tax inversion rules from Treasury

Tracy Staton The U.S. Treasury Department is rushing out a new set of guidelines on the "tax inversion" deals that have allowed drugmakers to save big money on taxes by buying ...

‘Pfizergan’ deal talks draw tax inversion opposition from Clinton, Trump

Carly Helfand Pfizer and Allergan–which both confirmed on Thursday that they're in "friendly" deal talks–may be intrigued with the prospect of a tie-up. But ...

AstraZeneca’s gout drug wins faint praise from FDA advisers

Damian Garde A majority of independent FDA advisers recommended approval for AstraZeneca's new gout drug, but not without noting that the treatment's safety profile presents ...

Boehringer looks for Pradaxa boost from now FDA-approved antidote

Carly Helfand The lack of an antidote to reverse the effects of new-age anticoagulants has kept some doctors from prescribing them. But now, Boehringer Ingelheim is hoping that'll ...

GSK says people and products were never in danger from Legionella bacteria in cooling towers

Eric Palmer GlaxoSmithKline says that the people and products at its manufacturing site in Zebulon, NC, were never in peril from the bacteria for Legionnaires' disease detected ...
Page 1 of 1412345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS